Uterine sarcomas

Pathology

Volumn 39, Issue 1, 2007, Pages 55-71

  Moinfar, Farid ^a   Azodi, Masood ^b   Tavassoli, Fattaneh A ^b  

^a UNIVERSITY OF GRAZ   (Austria)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiosarcoma; CD44 V3; Endometrial stromal sarcoma; ESS; FAL; Frequency of allelic loss; JAZF1 JJAZ1 fusion; Leiomyosarcoma; Liposarcoma; LMS; Rhabdomyosarcoma; Tamoxifen; UES; Undifferentiated endometrial sarcoma

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA CATENIN; CISPLATIN; DOXORUBICIN; FRIZZLED PROTEIN; FRIZZLED RELATED PROTEIN 4; GESTAGEN; IFOSFAMIDE; MESNA; UNCLASSIFIED DRUG;

ALLELE; ANGIOSARCOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; ENDOMETRIUM SARCOMA; GENE TRANSLOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MEDICAL INFORMATION; MOLECULAR DYNAMICS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT CARE; PLOIDY; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; UNDIFFERENTIATED CARCINOMA; UTERUS SARCOMA;

EID: 33847210715     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020601136146     Document Type: Article

References (152)

1. Gaducci A, Landoni F, Sartori E, et al. Uterine leiomyosarcoma: Analysis of treatment failures and survival. Gynecol Oncol 1996; 62: 25-32.
2. Gadducci A, Sartori E, Landoni F, et al. Endometrial stromal sarcoma: Analysis of treatment failures and survival. Gynecol Oncol 1996; 63: 247-53.
3. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986; 76: 399-402.
4. Major FJ, Blessing JA, Silverger SG, et al. Prognostic factors in early-stage uterine sarcoma: A Gynaecologic Oncology Group study. Cancer 1993; 71: 1702-9.
5. Rovirosa A, Ordi J, Ascaso C, et al. Prognostic factors in uterine sarcomas: A 21-year retrospective study at the Clinic and Provincial Hospital of Barcelona. Med Clin (Barc) 1998; 111: 172-6.
6. Yoonessi M. Endometrial stromal sarcomas. Cancer 1997; 40: 898-906.
7. Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20: 2758-60.
8. Tavassoli FA, Devilee P. Tumors of the Breast and Female Genital Tract. Pathology and Genetics. World Health Organization Classification of Tumors. Lyon: IARC, 2003.
9. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002; 12: 764-7.
10. Beer TW, Buchanan R, Buckley CH. Uterine stromal sarcoma following tamoxifen treatment. J Clin Pathol 1995; 48: 596.
11. Eddy GL, Mazur MT. Endolymphatic stromal myosis associated with tamoxifen use. Gynecol Oncol 1997; 64: 262-4.
12. Fisher B, Constantino JP, Redmon CK, Fisher ER, Wickerham L, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24. J Natl Cancer Inst 1994; 86: 527-37.
13. Gillett D. Leiomyosarcoma of the uterus in a woman taking adjuvant tamoxifen therapy. Med J Aust 1995; 163: 160-1.
14. Kennedy MM, Baigrie CF, Manek S. Tamoxifen and the endometrium: Review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology. Int J Gynecol Pathol 1999; 18: 130-7.
15. McCluggage WG, Varma M, Weir P, Bharucha H. Uterine leiomyosarcoma in patient receiving tamoxifen therapy. Acta Obstet Gynecol Scand 1996; 75: 593-5.
16. Okada DH, Rowland JB, Petrovic LM. Uterine pleomorphic rhabdomyosarcoma in a patient receiving tamoxifen therapy. Gynecol Oncol 1999; 75: 509-13.
17. Pang LC. Endometrial stromal sarcoma with sex cord-like differentiation associated with tamoxifen therapy. South Med J 1998; 91: 592-4.
18. Silva EG, Tornos CS, Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: The effects of tamoxifen. Int J Gynecol Pathol 1994; 13: 248-58.
19. Early Breast Cancer Trialists' Collaborative Group, Tamoxifen for early breast cancer. An overview of the randomized trials. Lancet 1998; 351: 1451-67.
20. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999; 353: 1993-2000.
21. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371-88.
22. Kloos I, Delaloge S, Pautier P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literature. Int J Gynecol Cancer 2002; 12: 496-500.
23. Yildirim Y, Inal MM, Sanci M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: Report of four cases. Int J Gynecol Cancer 2005; 15: 1239-42.
24. Madison T, Scottenfeld O, Baker V. Cancer of the corpus uteri in white and black women in Michigan 1985-1994 an analysis of trends in incidence and mortality and their relation to histologic subtype and stage. Cancer 1998; 83: 1546-54.
25. De Fusco PA, Gaffey TA, Malkasian GD Jr, Long HJ, Cha SS. Endometrial stromal sarcoma: Review of Mayo Clinic experience, 1945-1980. Gynecol Oncol 1989; 35: 8-14.
26. Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrickson MR. Primary uterine endometrial stromal sarcoma: A clinicopathology study of 117 cases. Am J Surg Pathol 1990; 14: 415-38.
27. McCluggage WG, Date A, Bharucha H, Toner PG. Endometrial stromal sarcoma with sex cord-like areas and focal rhabdoid differentiation. Histopathology 1996; 29: 369-74.
28. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001; 39: 273-8.
29. Nucci MR, O'Connell JT, Huettner PC, et al. h-Caldesmon effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol 2001; 25: 455-63.
30. Baker RJ, Hildebrandt RH, Rouse RV, et al. Inhibin and CD99 (MIC2) expression in uterine stromal neoplasms with sex-cord-like elements. Hum Pathol 1999; 30: 671-9.
31. Moinfar F, Regitnig P, Tabrizi AD, Denk H, Tavassoli FA. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms. Virchows Arch 2004; 444: 410-4.
32. Moinfar F, Kamerer-Gogg M, Sommersacher A, et al. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER1): potential basis for a new therapeutic approach. Am J Surg Pathol 2005; 29: 485-9.
33. Blom R, Malmstrom H, Guerrieri C. Endometrial stromal sarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases. Int J Gynecol Cancer 1999; 9: 98-104.
34. Hitchcock CL, Norris HJ. Flow cytometric analysis of endometrial stromal sarcoma. Am J Clin Pathol 1992; 97: 267-71.
35. Amant F, Moreman P, Cadron I, Hagemeijer A, Vergote I, Debiec-Rychter M. Endometrial stromal sarcoma with a sole t(X;17) chromosome change: Report of a case and review of the literature. Gynecol Oncol 2003; 88: 459-62.
36. Dal Cin P, Aly MS, De Wever I, Moreman P, Van Den Berghe H. Endometrial stromal sarcoma t(7;17)(p15-21;q12-21) is a non-random chromosome change. Cancer Genet Cytogenet 1992; 63: 43-6.
37. Hrynchak M, Horsman D, Salski C, Berean K, Benedet JL. Complex karyotypic alterations in an endometrial stromal sarcoma. Cancer Genet Cytogenet 1994; 77: 45-9.
38. Sonobe h, Iwata J, Furihata M, Ohtsuki Y, Taguchi T, Shimizu K. Endometrial stromal sarcoma with clonal complex chromosome abnormalities. Report of a case and review of the literature. Cancer Genet Cytogenet 1999; 112: 34-7.
39. Halbwedl I, Ulmann R, Kremser-ML, et al. Chromosomal alterations in low-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma as detected by comparative genomic hybridization. Gynecol Oncol 2005; 97: 582-7.
40. Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Sci USA 2001; 98: 6348-53.
41. Micci F, Walter CU, Teixeira MR, Panagopoulos I, Bjerkehagen B, Saeter G. Cytogenetic and molecular genetic analyses of endometrial stromal sarcoma: Nonrandom involvement of chromosome arms 6p and 7p and confirmation of JAZF1/JJAZ1 gene fusion in t(7;17). Cancer Genet Cytogenet 2003; 144: 119-24.
42. Hrzenjak A, Moinfar F, Tavassoli FA, et al. JAZF1/JJAZ1 gene fusion in endometrial stromal sarcomas. Molecular analysis by reverse transcriptase-polymerase chain reaction optimized for paraffin-embedded tissue. J Mol Diagn 2005; 7: 388-95.
43. Gunawan B, Shulten H-J, Fuzesi L. Identification of a BAC clone overlapping the t(6p12.3) breakpoint in the cell line ESS-1 derived from and endometrial stromal sarcoma. Cancer Genet Cytogenet 2003; 147: 84-6.
44. Moinfar F, Kremser ML, Man YG, Zatloukal K, Tavassoli FA, Denk H. Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the nontumerous normal-appearing endometrial and myometrial tissues. Gynecol Oncol 2004; 95: 662-71.
45. Hrzenjak A, Tipple M, Kremser ML, et al. Inverse correlation of secreted frizzled-related protein 4 and beta-catenin expression in endometrial stromal sarcomas. J Pathol 2004; 204: 19-27.
46. Bafico A, Grazit A, Pramila T, Finch PW, Yaniv A, Aoronson SA. Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signalling. J Biol Chem 1999; 274: 16180-7.
47. Wong SCC, Lo SFE, Lee KC, Yam JWP, Chan JKC, Hsiao WLW. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumors. J Pathol 2002; 196: 145-53.
48. Itoh T, Mochizuki M, Kumazaki S, Ishihara T, Fukayama M. Cystic pulmonary metastases of endometrial stromal sarcoma of the uterus, mimicking lymphangiomyomatosis: a case report with immunohistochemistry of HMB45. Pathol Int 1997; 47: 725-9.
49. Lissoni A, Cormio G, Bonazzi C, et al. Fertility-sparing surgery in uterine leiomyosarcoma. Gynecol Oncol 1998; 70: 348-50.
50. Piver MS, Rutledge FN, Copeland L, Webster K, Blumenson L, Suh O. Uterine endolymphatic stromal myosis: A collaborative study. Obstet Gynecol 1984; 64: 173-8.
51. Keen CE, Philip G. Progestogen-induced regression in low-grade endometrial stromal sarcoma. Case report and literature review. Br J Obstet Gynaecol 1989; 96: 1435-9.
52. Nordal RN, Kjorstad KE, Stenwig AE, Trope CG. Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976-1985. Int J Gynecol Cancer 1993; 3: 110-5.
53. Evans HL. Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer 1982; 50: 2170-82.
54. Bodner K, Bodner-Adler B, Obermair A, et al. Prognostic parameters in endometrial stromal sarcoma: A clinicopathologic study in 31 patients. Gynecol Oncol 2001; 81: 160-5.
55. de Nictolis M, Montironi R, Tommasoni S, Maggiera G. High-grade endometrial stromal sarcoma: Clinicopathologic and immunohistochemical study of a case. Pathologica 1994; 86: 217-21.
56. Leibsohn D, d'Ablaing G, Mishrll DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990; 162: 968-74.
57. Christopherson WM, Williamson EO, Gray LA. Leiomyosarcoma of the uterus. Cancer 1972; 29: 1512-7.
58. Covens AL, Nisker JA, Chapman WB, Allen HH. Uterine sarcoma: An analysis of 74 cases. Am J Obstet Gynecol 1987; 156: 370-4.
59. Hart WR, Craig JR. Rhabdomyosarcomas of the uterus. Am J Clin Pathol 1978; 70: 217-23.
60. Schwartz LB, Diamond MP, Schwartz PE. Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol 1993; 168: 180-3.
61. Wheelock JB, Krebs HB, Schneider V, Goplerud DR. Uterine sarcoma: Analysis of prognostic variables in 71 cases. Am J Obstet Gynecol 1985; 151: 1016-22.
62. Lee W-Y, Tzeng C-C, Chou C-Y. Uterine leiomyosarcomas coexistent with cellular and atypical leiomyomata in a young woman during the treatment with luteinizing hormone-releasing Hormone agonist. Gynecol Oncol 1994; 52: 74-9.
63. Parker WH, Fu YS, Berek JS. Uterine sarcomas in patients operated on for presumed leiomyomas and rapidly growing leiomyomas. Obstet Gynecol 1994; 83: 414-8.
64. Barter JF, Smith EB, Szpak CA, Hinshaw W, Clarke-Pearson DL, Creasman WT. Leiomyosarcoma of the uterus: Clinocopathologic study of 21 cases. Gynecol Oncol 1985; 21: 220-7.
65. Watanabe K, Hiraki H, OhishiM, et al. Uterine leiomyosarcoma with osteoclast-like giant cells: histopathological and cytological observations. Pathol Int 1996; 46: 656-60.
66. Aru A, Norup P, Bjerregaard B, Andreasson B, Horn T. Osteoclastlike giant cells in leiomyomatous tumors of the uterus. A case report and review of the literature. Acta Obstet Gynecol Scand 2001; 80: 371-4.
67. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms: A clinicopathologic study of 21 cases. Am J Surg Pathol 1994; 18: 576-82.
68. Major FJ, Blessing JA, Silverber SG, et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer 1993; 71 (Suppl): 1702-9.
69. th ed. New York: Springer, 2001; 580.
70. Atkins K, Bell S, Kewmpson R, Hendrickson M. Epithelioid smooth muscle neoplasms of the uterus. Mod Pathol 2001; 14: 132A.
71. Karpuz V, Joris F, Letovanec N, Branchmanski F, Kapanci Y. Metastizing low-grade clear cell leiomyosaracoma of the uterus. Pathol Int 1998; 48: 82-5.
72. Prayson RA, Hart WR. Mitotically active leiomyomas of the uterus. Am J Clin Pathol 1992; 97: 14-20.
73. Kurman RJ, Norris HJ. Mesenchymal tumors of the uterus. VI Epithelioid smooth muscle tumors including leiomyoblastoma and clear cell leiomyoma: a clinical and pathological analysis of 26 cases. Cancer 1976; 37: 1853-6.
74. Atkins K, Bell S, Kempson R, Hendrickson M. Myxoid smooth muscle neoplasms of the uterus. Mod Pathol 2001; 14: 132A.
75. Chen KT. Myxoid leiomyosarcoma of the uterus. Int J Gynecol Pathol 1984; 3: 389-92.
76. King ME, Dickersin GR, Scully RE. Myxoid leiomyosarcoma of the uterus. A report of six cases. Am J Surg Pathol 1982; 6: 589-98.
77. Peacock G, Archer S. Myxoid leiomyosaracoma of the uterus: case report and review of the literature. Am J Obstet Gynecol 1989; 160: 1515-8.
78. Kunzel KE, Mills NZ, Muderspach LI, d'Ablaing G III. Myxoid leiomyosarcoma of the uterus. Gynecol Oncol 1993; 48: 277-80.
79. Schneider D, Halperin R, Segal M, Maymon R, Bukovsky I. Myxoid leiomyosarcoma of the uterus with unusual malignant histologic pattern: a case report. Gynecol Oncol 1995; 59: 156-8.
80. Darby AJ, Papadaki L, Beilby JO. An unusual leiomyosarcoma of the uterus containing osteoclast-like giant cells. Cancer 1975; 36: 495-504.
81. Evans N. Malignant myomata and related tumors of the uterus. Surg Gynecol Obstet 1920; 30: 225-39.
82. Marshall RJ, Braye SG, Jones DB. Leiomyosarcoma of the uterus with giant cells resembling osteoclasts. Int J Gynecol Pathol 1986; 5: 260-8.
83. Patai K, Illyes G, Varbiro S, Gidai J, Kosa L, Vajo Z. Uterine leiomyosarcoma with osteoclast like giant cells and long standing systemic symptoms. Gynecol Oncol 2006; 102: 403-5.
84. Pilon VA, Parikh N, Maccera J. Malignant osteoclast-like giant cell tumor associated with a uterine leiomyosarcoma. Gynecol Oncol 1986; 23: 381-6.
85. Chen KTK. Leiomyosarcoma with osteoclast-like giant cells (letter). Am J Surg Pathol 1995; 19: 487-8.
86. Sieinski W. Malignant giant cell tumor associated with leiomyosarcoma of the uterus. Cancer 1990; 65: 1838-42.
87. Bodner K, Bodner-Adler B, Kimberger O, et al. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathologic parameters. Anticancer Res 2003; 23: 729-32.
88. Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in leiomyomata and leiomyosarcoma. Cancer 2004; 101: 11455-62.
89. Sutton GP, Stehman FB, Michael H, et al. Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol 1986; 68: 709-15.
90. Poncelet C, Walker F, Madelenat P, et al. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: A possible diagnostic tool for the diagnosis of leiomyosarcoma. Hum Pathol 2001; 32: 1190-6.
91. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Leiomyosarcoma. Cancer Genet Cytogenet 2005; 161: 1-19.
92. Packenham JP, du Manoir S, Schrock E, et al. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. Mol Carcinog 1997; 19: 273-9.
93. Quade BJ, Pinto AP, Howarad DR, et al. Frequent loss of heterozygosity for chromosome 10 in uterine leiomyosarcoma in contrast to leiomyoma. Am J Pathol 1999; 154: 949-50.
94. Quade BJ, Wang TY, Sornberger K, et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2005; 40: 97-108.
95. Esposito NN, Hunt JL, Bakker A, Jones MW. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors. Am J Surg Pathol 2006; 3: 97-103.
96. Quade BJ. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions. Curr Opin Obstet Gynecol 1995; 7: 35-42.
97. Rose PG, Piver MS, Tsukada Y, Lau T. Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer 1989; 63: 935-8.
98. Fleming WP, Peters WA, Kumar NB, Morley GW. Autopsy findings in patients with uterine sarcoma. Gynecol Oncol 1984; 19: 168-72.
99. Goff BA, Rice LW, Fleischhacker D, et al. Uterine leiomyosarcoma and endometrial stroma sarcoma: Lymph node metastases and sites of recurrence. Gynecol Oncol 1993; 50: 105-9.
100. Evans HL, Chawla SP, Simpson C, Finn KP. Smooth muscle neoplasm of the uterus other than ordinary leiomyoma: A study of 46 cases, with emphasis on diagnostic criteria and prognostic factor. Cancer 1988; 62: 2239-47.
101. Vardi JR, Tovell HMM. Leiomyosarcoma of the uterus: A clinicopathologic study. Obstet Gynecol 1980; 56: 428-34.
102. Blom R, Guerrieri C, Stal O, Malmstrom H, Simonsen E. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998; 68: 54-61.
103. Kahanpaa KV, Wahlstrom T, Grohn P, et al. Sarcomas of the uterus: A clinicopathologic study of 119 patients. Obstet Gynecol 1986; 67: 417-24.
104. Marchese MJ, Liskow AS, Crum CP, et al. Uterine sarcomas: A clinicopathologic study, 1965-1981. Gynecol Oncol 1984; 18: 299-312.
105. Larson B, Silfversward C, Nilsson B, Petterson F. Prognostic factors in uterine leiomyosarcoma: A clinicopathologic study of 143 cases. The Radiumhemmet series, 1936-1981. Acta Oncol 1990; 29: 185-91.
106. Nordal RR, Kristensen GB, Kaern J, et al. The prognostic significance of stage, tumor size, cellular atypia and DAN ploidy in uterine leiomyosarcoma. Acta Oncol 1995; 34: 797-802.
107. Hart WR, Billman JK Jr. A reassessment of uterine neoplasm originally diagnosed as leiomyosarcomas. Cancer 1978; 41: 1902-10.
108. Mayerhofer K, Obermair A, Windbichler G, et al. Leiomyosarcoma of the uterus: A clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999; 74: 196-201.
109. Pautier P, Genmestie C, Rey A, et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000; 88: 1425-31.
110. Layfield LJ, Liu K, Dodge R, Barsky SH. Uterine smooth muscle tumor. Utility of classification by proliferation, ploidy and prognostic markers versus traditional histopathology. Arch Pathol Lab Med 2000; 124: 221-7.
111. Olah KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynecol 1992; 99: 590-4.
112. Levenback C. Rubin SC, McCormick PM, et al. Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol 1992; 45: 202-5.
113. Kanejekal S, Chambers A, Fung MF, Verma S. Systemic therapy for advanced uterine sarcoma: a systemic review of the literature. Gynecol Oncol 2005; 97: 624-37.
114. Berchuck A, Rubin SC, Hoskins WJ, et al. Treatment of uterine leiomyosarcoma. Obstet Gynecol 1988; 71: 845-50.
115. Hannigan EV, Gomez LG. Uterine leiomyosarcoma: A review of prognostic clinical and pathologic features. Am J Obstet Gynecol 1979; 134: 557-64.
116. Holcomb K, Francis M, Ruiz J, Abulafia O, Matthews RP, Lee YC. Pleomorphic rhabdomyosarcoma of the uterus in a postmenopausal woman with elevated serum CA125. Gynecol Oncol 1999; 74: 499-501.
117. Kulka EW, Douglas GW. Rhabdomyosarcoma of the corpus uteri: Report of a case, associated with adenocarcinoma of the cervix, with review of the literature. Cancer 1952; 5: 727-36.
118. McCluggage WG, Lioe TF, McClelland HR, Lamki H. Rhabdomyosarcoma of the uterus: Report of two cases, including one of the spindle cell variant. Int J Gynecol Cancer 2002; 12: 128-32.
119. Ordi J, Stamatakos MD, Tavassoli FA. Pure pleomorphic rhabdomyosarcomas of the uterus. Int J Gynecol Pathol 1997; 16: 369-77.
120. Podczaski E, Sees J, Kaminski P, et al. Rhabdomyosarcoma of the uterus in a postmenopausal patient. Gynecol Oncol 1990; 37: 439-42.
121. Borka K, Patai K, Rendek A, Sobel G, Paulin F. Pleomorphic rhabdomyosarcoma of the uterus in a postmenopausal patient. Pathol Oncol Res 2006; 12: 102-4.
122. Chiarle R, Godio L, Fusi D, et al. Pure alveolar rhabdomyosarcoma of the corpus uteri: description of a case with serum level of CA-125. Gynecol Oncol 1997; 66: 320-3.
123. Ng TY, Loo KT, Leung TW, et al. Alveolar rhabdomyosarcoma of the cervix. Gynecol Oncol 2003; 91: 623-6.
124. Ojwang SB, Rana F, Sayed S, Aruasa WK. Embryonal rhabdomyosarcoma with uterine inversion: Case report. East Afr Med J 2006; 83: 110-3.
125. Montag TW, D'Ablaing G, Schlaerth JB, et al. Embryonal rhabdomyosarcoma of the uterine corpus and cervix. Gynecol Oncol 1986; 25: 171-94.
126. Mendez LE, Joy S, Angioli R, Estape R, Penalver M. Primary uterine angiosarcoma. Gynecol Oncol 1999; 75: 272-6.
127. Schammel DP, Tavassoli FA. Uterine angiosarcomas: A morphologic and immunohistochemical study of four cases. Am J Surg Pathol 1998 Feb; 22(2): 246-50.
128. Karateke A, Gurbuz A, Kabaca C, Alkan A, Kir G, Cetiner H. Uterine liposarcoma in a young woman: A case report. Int J Gynecol Cancer 2005; 15: 1230-4.
129. Obafunwa JO, Uguru VE. Liposarcoma of the cervix. Trop Geogr Med 1990; 42: 90-1.
130. Bapat K, Brustein S. Uterine sarcoma with liposarcomatous differentiation: Report of a case and review of the literature. Int J Gynaecol Obstet 1989; 28: 71-5.
131. Levine PH, Wei XJ, Gagner JP, Flax H, Mittal K, Blank SV. Pleomorphic liposarcoma of the uterus: Case report and literature review. Int J Gynecol Pathol 2003; 22: 407-11.
132. Carter ER, McDonald JR. Uterine mesodermal mixed tumors. Am J Obstet Gynecol 1960; 80: 368-73.
133. Middlebrook LF, Tennant R. Rhabdomyosarcoma of uterine corpus: Report of 2 cases. Obstet Gynecol 1968; 32: 537-42.
134. Lurain AR, Monroe T. Mixed mesodermal sarcoma of the corpus uteri associated with bilateral thecoma. Am J Obstet Gynecol 1959; 78: 613-7.
135. Ober WB, Tovel HMM. Mesenchymal sarcomas of the uterus. Am J Obstet Gynecol 1959; 77: 246-68.
136. Edwards DL, Sterling LN, Keller RH, Nolan JF. Mixed heterologous mesenchymal sarcomas (mixed mesodermal sarcomas) of the uterus: Addition of 7 cases. Am J Obstet Gynecol 1963; 85: 1002-11.
137. Donkers KazzazBA, Meijering JH. Rhabdomyosarcoma of the corpus uteri: Report of two cases with review of the literature. Am J Obstet Gynecol 1972; 114: 1025-30.
138. Siegal GP, Taylor III LL, Nelson KG, et al. Characterization of a pure heterologous sarcoma of the uterus: Rhabdomyosarcoma of the corpus. Int J Gynecol Pathol 1983; 2: 303-15.
139. Lloyd RV, Hajdu SI, Knapper WH. Embryonal rhabdomyosarcoma in adults. Cancer 1983; 51: 557-65.
140. Jaworski RC, Rencoret RH, Moir DH. Pleomorphic rhabdomyosarcoma of the uterus: Case report with a review of the literature. Br J Obstet Gynaecol 1984; 91: 1269-73.
141. Scheidt P, Moerman PH, Vergote I. Rhabdomyosarcoma of the corpus of the uterus: A case report. Eur J Gynaecol Oncol 2000; 21: 371-3.
142. Behtash N, Mousavi A, Tehranian A, Khanafshar N, Hanjani P. Embryonal rhabdomyosarcoma of the uterine cervix: Case report and review of the literature. Gynecol Oncol 2003; 91: 452-5.
143. Reynolds EA, Logani S, Moller K, Horowitz IR. Embryonal rhabdomyosaracoma of the uterus in a postmenopausal woman. Case report and review of the literature. Gynecol Oncol 2006; 103: 736-9.
144. Witkin GB, Askin FB, Geratz JD, Reddick RL. Angiosarcoma of the uterus: a light microscopic, immunohistochemimcal and ultrastructural study. Int J Gynecol Pathol 1987; 6: 176-84.
145. Milne DS, Hinshaw K, Malcom AJ, Hilton P. Primary angiosarcoma of the uterus: A case report. Histopathology 1990; 16: 203-5.
146. Quinonez GE, Paraskevas MP, Diocee MS, Lorimer SM. Angiosarcoma of the uterus: A case report. Am J Obstet Gynecol 1991; 164: 90-2.
147. Tallini G, Price FV, Carcangiiu ML. Epithelioid angiosarcoma arising in uterine leiomyomas. Am J Clin Pathol 1993; 100: 514-8.
148. Drachenberg CB, Faust FJ, Borkowski A, Papadimitriuo JC. Epitheliod angiosarcoma of the uterus arising in the leiomyoma with associated ovarian and tubal angiomatosis. Am J Clin Pathol 1994; 102: 388-9.
149. Veliath AJ, Hannah P, Ratnakar C, Jayanthi K, Aurora AL. Primary liposarcoma of the cervix: A case report. Int J Gynaecol Obstet 1978; 16: 79-9.
150. Schmidt C, Doroszewski AW. Liposarcoma of the uterus. A case report. Geburtshilfe Frrauerheilkd 1996; 56: 262-4.
151. Schneebauer J, Brinninger G, Halabi M, Nagi F. Liposarcoma of the uterus. Gynakol Geburtshilfliche Rundsch 1996; 36: 90-1.
152. Takeuchi K, Murata K, Funaki K, Fujita K, Hayakawa Y, Kitazawa S. Liposarcoma of the uterine cervix: case report. Eur J Gynaecol Oncol 2000; 21: 290-1.